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ABSTRACT
Sequencingpathogengenomesiscostly,demanding
careful allocation of limited sequencing resources.
We built a computational Sequencing Analysis
Pipeline (SAP) to guide decisions regarding the
amountofgenomicsequencingnecessarytodevelop
high-quality diagnostic DNA and protein signatures.
SAP uses simulations to estimate the number of
target genomes and close phylogenetic relatives
(near neighbors or NNs) to sequence. We use SAP
to assess whether draft data are sufficient or finished
sequencing is required using Marburg and variola
virus sequences. Simulations indicate that inter-
mediate to high-quality draft with error rates of
10
 3–10
 5( 83coverage)oftargetorganismsissuit-
able for DNA signature prediction. Low-quality draft
with error rates of  1% (33 to 63 coverage) of target
isolates is inadequate for DNA signature prediction,
althoughlow-qualitydraftofNNsissufficient,aslong
as the target genomes are of high quality. For protein
signatureprediction,sequencingerrorsintargetgen-
omessubstantiallyreducethedetectionofaminoacid
sequence conservation, even if the draft is of high
quality. In summary, high-quality draft of target and
low-quality draftofNNsappearstobeacost-effective
investmentforDNAsignatureprediction,butmaylead
to underestimation of predicted protein signatures.
INTRODUCTION
Draft sequencing requires that the order of base pairs in cloned
fragments of a genome be determined usually at least four
times (4· depth of coverage) at each position for a minimum
degree of draft accuracy. This information is assembled into
contigs, or fragments of the genome that cannot be joined
further due to lack of sequence information across gaps
between the contigs. To generate high-quality draft, usually
 8· coverage is optimal (1). Finished sequence, without gaps
or ambiguous base calls, usually requires 8· to 10· coverage,
along with additional analyses, often manual, to orient the
contigs relative to one another and to close the gaps between
them in a process called ﬁnishing. In fact, it has been stated
that ‘the deﬁning distinction of draft sequencing is the avoid-
ance of signiﬁcant human intervention’ (1), although there are
computational tools that may also be capable of automated
ﬁnishing in some circumstances (2).
While some tabulate the cost differential between high-
quality draft versus ﬁnished sequences to be 3- to 4-fold,
and the speed differential to be >10-fold (1), others state that
the cost differential is a more modest 1.3- to 1.5-fold (3). In
either case, draft sequencing is cheaper and faster. Experts
havedebatedwhetherﬁnishedsequencingisalwaysnecessary,
considering the higher costs (1,3,4).
Thus, here we set out to determine whether draft sequence
dataareadequateforthecomputationalpredictionofDNAand
protein diagnostic signatures. By a ‘signature’ we mean a short
region of sequence that is sufﬁcient to uniquely identify an
organism down to the species level, without false negatives
due to strain variation or false positives due to cross reaction
with close phylogenetic relatives. In addition, for DNA sig-
natures, we require that the signature be suitable for a TaqMan
reaction (e.g. composed of two primers and a probe of the
desired Tms). Limited funds and facilities in which to sequence
biothreat pathogens mean that decision makers must choose
wisely which and how many organisms to sequence. Money
and time saved as a result of draft rather than ﬁnished sequen-
cing enables more target organisms, more isolates of the target
and more near neighbors (NNs) of the target to be sequenced.
However, if draft data do not facilitate the generation of high-
quality signatures for detection, the tradeoff of quantity over
quality will not be worth it.
We used the Sequencing Analysis Pipeline (SAP) (5,6) to
compare the value of ﬁnished sequence, real draft sequence
and simulated draft sequence of different qualities for the
computational prediction of DNA and protein signatures for
pathogen detection/diagnostics. Marburg and variola viruses
were used as model organisms for these analyses, due to the
availability of multiple genomes for these organisms. We hope
that variola may serve as a guide for making predictions about
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thus the cost of sequencing is much higher than for viruses.
Variola was selected as the best available surrogate for bac-
teria at the time we began these analyses because:
i.it is double-stranded DNA;
ii.it has a relatively low mutation rate, more like bacteria than
liketheRNAorshorterDNAvirusesthathavehighermuta-
tion rates and thus higher levels of variation;
iii.it is very long for a virus, albeit shorter than a bacterial
genome;
iv.wehaveaccesstomanygenomes,whichweresequencedby
our collaborators at the US Centers for Disease Control and
Prevention in Atlanta, GA;
v.there are finished genomes available, so we can compare
actual finished data with simulated draft data.
Only recently have a fairly large number of Bacillus anthracis
genomes become available to us. However, since only some of
these are ﬁnished, currently we cannot compare ﬁnished with
draft results for this bacterial genome.
MATERIALS AND METHODS
The sequencing analysis pipeline uses the DNA and
protein signature pipelines
The draft SAP simulations are nearly identical to those using
ﬁnished genomes, described previously (5,6). The SAP
(Figure 1) performs stochastic (Monte Carlo) simulations
and includes our DNA and Protein Signature Pipelines as
components, which will be summarized brieﬂy below. It is
necessary to describe what the signature pipelines do before
the SAP can be clearly described, so signature pipelines will
be discussed ﬁrst. As a step within the DNA and Protein
Signature Pipelines, DNA sequence alignments of multiple
draft genomes are required. For this we use the WGASA
software, also summarized below. Once each of these com-
ponents of the SAP has been presented, the SAP itself will be
described.
DNA signature pipeline
The DNA Signature Prediction Pipeline, described in detail
elsewhere (7–10), ﬁnds sequence regions that are conserved
among target genomes by creating a consensus based on a
multiple sequence alignment. WGASA is the software used
in the analyses here to create an alignment and will be dis-
cussed below. Next, the DNA Signature Pipeline identiﬁes
regions that are unique in the target sequence consensus rel-
ative to all other non-target bacterial and viral sequences that
we have in a >1Gb database, which is frequently updated from
the NCBI GenBank sequence database (11) and other sources
(e.g. our collaborators at the CDC, USDA and other public
sources, such as TIGR, Sanger Institute and the Joint Genome
Institute). From the conserved, unique regions, signatures are
selected based on the requirements of a particular technology,
in this case, TaqMan PCR. These signature candidates may
then proceed for further in silico screening (BLAST analyses
to look for undesired inexact matches) before undergoing
laboratory screening.
Figure 1. Diagram of the SAP. For an SAP run, first a pool of target genome and a pool of NN genomes are collected. Then many random subsamples of target and
NNgenomesareselectedfromthepool,andeachsubsampleisrunthrougheithertheDNAsignaturepipelineortheproteinsignaturepipeline,whichidentifyregions
conserved among target genomes and unique relative to non-target genomes, where unique regions are evaluated by comparing to a large sequence database of all
currently available bacterial and viral complete genomes or the non-redundant protein database, excluding NNs from the NN pool that are not in that random
subsample.Thus,each run of the SAPrequires manyruns of the DNA or proteinsignaturepipelineswith differentrandom samples,generatinga rangeof outcomes
that are plotted on range plots.
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Protein signature prediction and SAP methods have previously
been described in detail (6). The following brieﬂy describes
the procedure. First, target genomes are aligned using
WGASA. A set of gene (start, end) pairs for both the plus
and minus strands relative to the reference genome is required.
This implies that coding frames for the translation of nucleic
acid codons into amino acids for each protein of the target
organism’s genome have been correctly determined. From
the aligned genomes, nucleotide codons are translated into
amino acid sequence based on the gene locations, and con-
served strings of six or more amino acids among all the target
genomes are recorded. These conserved fragments are then
compared with the NCBI GenBank non-redundant (nr) data-
base of amino acid sequences, unveiling peptides that are
unique to the target species. For our computations, we require
that if a peptide signature is longer than six amino acids, then
every sub-string of length six amino acids is also conserved
and unique. There may be many conserved and unique peptide
signatures on the same and on different proteins. The resulting
conserved, unique peptides that are at least six amino acids
long from open reading frames are considered to be protein
signature candidates.
Signature peptides may be used as targets for antibody or
ligand binding and may be developed for use in detection,
therapeutics or vaccines (12,13). Since the signature regions
are highly conserved within a species, it is likely that they
are functionally important to the organism’s survival or repro-
duction. Those signatures that land on or near protein active
sites may be developed into therapeutics, since antibody or
ligand binding may interfere with protein function. Signature
regions may even be considered as vaccine targets, since
these unique peptides may evoke a speciﬁc response in the
host (14,15).
WGASA, a new sequence alignment tool
For draft genomes, WGASA, or Whole Genome Analysis
through Scalable Algorithms, is used to align multiple
sequences. This is the only available tool that enables multiple
sequence alignment of draft genomes and that is capable of
aligning largeor many genomes. WGASA requiresatleast one
ﬁnished reference genome and the others may be draft.
Only recently has it become possible to use the DNA
Signature Pipeline to predict signature candidates for draft
genomes. This capability is due to the invention of software
for multiple sequence alignment of draft genomes with at
least one completed full genome. WGASA was developed
by David Hysom, Chuck Baldwin and Scott Kohn in the
Computations directorate at Lawrence Livermore National
Laboratory. They designed the software in close communica-
tion with members of our bioinformatics team, and it is
tailored for our needs of generating diagnostic and forensic
pathogen signatures.
WGASA can efﬁciently align large (e.g. bacterial)
genomes. In addition, the developers have created a parallel
version that runs in minutes, allowing the SAP simulations,
involving thousands of calls to WGASA, to complete in a
feasible time frame. In addition to the SAP analyses, this
tool has enabled us to revisit signature predictions for several
important organisms, such as the food-borne pathogen
Listeria, that were previously problematic because some of
the sequences were available only in draft format.
The tool requires that there be one or more complete,
ﬁnished genome, and any number of draft sequences. It is
based on sufﬁx-tree algorithms (16). It requires that anchors,
identical sequence fragments of user-speciﬁed length, be
found in each of the genomes to be aligned. Thus, there
must be some level of sequence conservation among
the genomes in order to discover anchors of sufﬁcient length
(e.g. 35–60 bp) that are present in all the genomes. Then the
regions between the anchors are aligned using a tool, such as
clustalw or HMMer. The algorithm functions most efﬁciently
if anchors are frequent and dispersed across the genomes to
provide even coverage. If substitutions, deletions, insertions or
gaps in sequence information (e.g. between contigs) result in
an anchor’s absence in one or more of the genomes, then those
regions must be aligned using clustalw, which is slower and
more memory intensive for large amounts of sequence data.
Similar to all anchor-based alignment algorithms, WGASA is
dependent upon a high degree of co-linearity across all input
genomes.
SAP
DNA analyses
The SAP for DNA signature analyses operates as follows.
First, all available complete genomes of target were gathered
intoa poolwith the totalgenome count called T.Asecondpool
was created of all available NN complete genomes, with the
totalcount ofsequencescalledN.Next,we selected 10random
samples of size t targets and n NNs, for all t ranging from 1 to
T and all n ranging between 1 and minimum(10,N). We ran
the DNA Signature Prediction Pipeline for each sample, with
signature prediction based on conservation among the t target
strains and uniqueness relative to a >1 Gb database minus
those NNs in the NN pool that were not chosen in that sample.
Thus, for each sample, signature candidates were predicted as
though we had only t target and n NN sequences, as well as the
rest of the less-closely related organisms in our database that
are not considered NNs. In addition to the number of TaqMan
signature candidates, the fraction of the genome that is con-
served among the t target sequences was also calculated.
Based on the combined results of the many signature pipeline
runs using random target samples of size t and n, we assessed
how much sequence data, that is, the values of t and n, was
required to approximate the number of signature candidates c
that were predicted when the full data set (all target and NN
sequences, t ¼ T and n ¼ N) was analyzed with the signature
pipeline. Using the full data set will yield the fewest signa-
tures, because lack of conservation or uniqueness will winnow
away all unsuitable candidates.
Thus, the SAP performs Monte Carlo sampling from the
target and NN genomes, runs each sample through the signa-
ture pipeline and summarizes the results of the hundreds of
signature pipeline runs in a single plot. On our 24 CPU Sun
server, up to seven signature pipeline simulations may be run
in parallel, each requiring  15–22 min for viral genomes. All
of the SAP analyses of dozens of bacteria and viruses to date
have used a total run time of 6.26 years (operating in parallel),
with an average pipeline run time of 0.522 h, and a process
time span of 2.32 years.
5840 Nucleic Acids Research, 2005, Vol. 33, No. 18The span of predictions generated by different random
samples of genomes is illustrated using range plots
(Figures 2–8). Along the y-axis, whole numbers represent
the number of target strains t and the incremental values
between the integers represent the number n of NN genomes.
Only Figures 3, 5 and 6 have the incremental n values, because
for the other plots of target sequence conservation only, the
number of NNs was not relevant, and for the protein analyses
NN comparisons were not made (described below). Outcomes
of the number of signature candidates or the fraction of the
target genome that is conserved are plotted along the x-axis as
horizontal lines spanning the range (of predicted numbers of
signatures or fraction conserved) for the s random samples of
size (t,n) with the median and quantiles of the range indicated
by colored, short vertical lines. If a random sample of t target
strainsandnNNstrainswere sequenced, therewouldbea90%
chance that the number of signature candidates for that sample
would be less than or equal to the 90% quantile mark. The
expected outcome is a reduction in the number of signature
candidates or the fraction of the genome that is conserved as
the number of target and NN sequences used in the simulations
increases, due to a reduction in conservation from additional
targets and a reduction in uniqueness from additional NNs.
Protein analyses
The SAP analyses for proteins proceed much like that for
DNA signatures. Random samples of size t target sequences
are generated, where t ranges from 1 to T, the total number of
target sequences in the pool. Either ﬁnished data, actual draft
data, or draft data simulated as described below are aligned
using WGASA. The protein signature prediction pipeline is
run on each random sample, and the range, median, 75th and
90th quantiles of the number of protein signature candidates
for the samples of a given target size t is plotted in range plots
as described above.
Our DNA SAP analyses examined the effects of both the
number of target as well as the number of NN sequences, but
Figure 3. Range plots as described in the methods for the number of TaqMan signature candidates for Marburg virus for (A) finished and (B) draft sequences. To
discriminatesamplesinwhichzeroNNswereused,therangeisdrawnasahorizontalgrayline,andwhenn > 0,therangeisdrawnasablackline.Thebestestimate
ofthetruevalueisthequalitymeasuredeterminedusingtheentiretargetandNNpools,andisrepresentedbya verticalblackline.Thisbestestimateplusaconstant
c ¼ 20 is at the location of the vertical dashed line and was selected to indicate a reasonable distance from the true answer. The 75% quantile for each range is
shown with a black, vertical tick mark.
Figure 2. Range plots of the conserved fraction of the target genome for Marburg virus (A) finished sequences and (B) draft sequences. The range of values from
different random samples for a given sample size (number of target sequences) is drawn as a horizontal line. The 75th quantile of each range is marked with a
short vertical tick. The conserved fraction using all of the target sequences is given in the box labeled ANS (for ‘answer’) and marked with a vertical line along this
value on the x-axis.
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number of target sequences. This is because composing the
lists of NN proteins for random, temporary exclusion from
the protein nr database (to estimate the value of that NN
sequence data) would be difﬁcult to automate for rapid,
high-throughput computations. Thus, we compared the target
proteins with all the proteins in nr, regardless of their phylo-
genetic relationship to the target. This was comparable with
DNA SAP results using all available NN data.
THE SEQUENCE DATA
Actual draft: Marburg virus
We had sequence data for four strains of Marburg virus, both
the actual draft and the ﬁnished versions of those same isol-
ates, provided for these analyses by a colleague working at
Lawrence Livermore National Laboratory. The draft sequence
was of  3· to 6· coverage, which enabled us to compare SAP
results using the same strains in ﬁnished form. The identities
of these sequences are provided in the Appendix. For the draft
Marburg analyses, we selected one ﬁnished strain, the refer-
ence strain from GenBank (gi|13489275|ref|NC_001608.2|
Marburg virus, complete genome), as the WGASA reference
genome, and then used random sub-samples from the four
draft genomes. Marburg was the only organism for which
we could obtain a sufﬁcient number of draft genomes for
the SAP Monte Carlo simulations. A total of 814 simulations
for DNA signatures, i.e. individual runs of the DNA signature
pipeline, and 48 simulations for protein signatures were per-
formed using Marburg ﬁnished and draft data, requiring an
average of 15 min per simulation.
Simulated draft: variola virus
We used ﬁnished sequence data generously provided by col-
laborators at the US CDC for 28 variola major genomes and
22 NN genomes from the Orthopox family. The sequence
identities are provided in the Appendix. Since we did not
have real draft data available, we developed a program to
simulate draft sequence from ﬁnished sequence, based on
guidance from two colleagues who have been involved in
sequencing efforts and the ﬁnishing process in the Biology
and Biotechnology Research Program at Lawrence Livermore
National Laboratory. In outline, the draft simulator program
randomly cuts a genome into contigs of a size randomly
Figure 4. Rangeplots forthe conservedfractionofthe target genomeforvariolavirusfor(A) finishedsequence,(B) simulateddraftsequencewitha low error rate,
(C) simulated draft with an intermediate error rate and (D) simulated draft with a high error rate.
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tion also determines whether there are gaps or overlaps
between contigs, as well as the size of the gap or overlap.
Sequencing errors are also simulated.
The following paragraphs describe the draft simulation
process in greater detail. First, the 50 end of the sequence is
simulated as missing or present according to a random
(Bernoulli) trial based on the probability of there being a
gap in the sequence data. If simulations randomly determine
that the ﬁrst part of the sequence is missing, then the size of
the missing segment is selected randomly from a uniform
distribution ranging from the minimum gap size to the
maximum gap size. The length of the ﬁrst contig is selected
randomly from an exponential distribution with a non-zero
minimum contig size and a maximum contig size that is a
fraction of the mean genome length for the species. The
mean of this exponential distribution is also speciﬁed as a
fraction of the mean genome length.
Next, a random Bernoulli trial again determines whether
there is a gap or overlap between the ﬁrst and second contigs,
and the size of the gap or overlap is chosen from the appro-
priate uniform distribution (range for gap size ¼ 1–2000
bases, range for overlap size ¼ 20–40 bases). The size of
the contig is selected from the exponential distribution as
described above. Additional contigs are simulated in a similar
manner.
Within each contig, sequencing errors are simulated based
on the size of the contig, and whether the base position is at an
end (ﬁrst or last 100 bases) or in the middle of the contig. For
long, double-stranded DNA viruses (e.g. variola) and bacteria,
the sequencing error rates are larger at the beginning and end
of a contig than in the middle, and small contigs are more
likely to contain sequencing errors than are large contigs. In
contrast, due to differences in generating the products for
Sanger sequencing that are employed for smaller RNA and
DNA viruses, there are often more sequencing errors in the
middle of contigs for such smaller viral draft genomes.
Although we did not speciﬁcally simulate draft for RNA
and short DNA viruses, our simulator should work with
minor modiﬁcation to a few parameters. Thus, there are
Figure 5. Range plots for the number of TaqMan signature candidates for variola virus (A) finished target and NN sequences, (B) simulated draft target and NN
sequenceswithalowerrorrate,(C)simulateddrafttargetsequenceswithalowerrorrateanddraftNNsequenceswithahigherrorrateand(D)simulateddrafttarget
sequences with an intermediate error rate and draft NN sequences with a high error rate.
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cing errors: (i) the size cutoff for small versus large contigs,
(ii) the probability of errors in the middle portion of small
versus large contigs, (iii) the length of the contig ends where
sequencing is either less accurate (bacteria and long double-
stranded DNA viruses) or more accurate (small viruses, RNA
viruses) and (iv) the probability of sequencing errors at the
contig ends. If there is a sequencing error at a particular base,
we assumed that that base is randomly changed to one of the
other three bases with equal probability. Although additional
features could be added to the draft simulation tool, the stoch-
astic features that we have incorporated capture the main
features of draft sequence and produce data that are suitable
for SAP analyses.
We performed six sets of analyses using simulated variola
draft. Three sets of simulated variola draft runs of the SAP
used the following parameters:
probability of a gap between contigs ¼ 0.95;
probability of overlap between contigs ¼ 0.05;
minimum gap size if there is a gap (uniform distribution) ¼
1 bp;
maximum gap size ¼ 2000 bp;
minimum overlap if there is overlap (uniform dis-
tribution) ¼ 20 bp;
maximum overlap ¼ 40 bp;
minimum contig size (exponential distribution) ¼ 2000 bp;
maximum contig size ¼ 0.5 · (mean genome length) bp
mean contig size ¼ 0.05 · (mean genome length) bp
cutoff size for small versus large contigs ¼ 10000 bp;
probability of sequence errors inside large contigs ¼ 0.01;
probability of sequence errors inside small contigs ¼ 0.05;
Figure6. RangeplotsforthenumberofTaqMansignaturecandidatesforvariolavirus(A)simulateddrafttargetwithahigherrorrateandfinishedNNs,(B)finished
target and draft NNs with a high error rate and (C) draft target and draft NNs with a high error rate.
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probability of sequence errors in the contig ends ¼ 0.20;
We will refer to the above set of simulations as those with
a high probability of sequencing errors, or low-quality draft.
The other three simulated variola draft runs used all the same
parameters as above, except that the sequencing error rates
were dramatically lower, more in line with error rates of 10
 5/
base that the US Centers for Disease Control and Prevention
(CDC) has indicated for their draft variola genomes:
probability of sequence errors inside large contigs ¼ 10
 5;
probability of sequence errors inside small contigs ¼ 10
 4;
probability of sequence errors in the contig ends ¼ 10
 3;
Figure 8. Range plots for the number of protein signature candidates for variola virus (A) finished sequence, (B) simulated draft target sequence with a low error
rate, and (C) simulated draft target sequence with an intermediate error rate and (D) simulated draft target sequence with a high error rate.
Figure 7. Range plots for the number of protein signature candidates for Marburg virus (A) finished and (B) draft sequence data.
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quality draft. Finally, we performed SAP runs using high
error rate (low quality) simulated draft of the NN sequences
and intermediate quality simulated draft of target genomes,
using the following probabilities of sequencing errors:
probability of sequence errors inside large contigs ¼ 10
 3;
probability of sequence errors inside small contigs ¼ 10
 3;
probability of sequence errors in the contig ends ¼ 10
 3;
The intermediate quality simulated draft is consistent with
error rates for draft sequencing cited in the literature (1,3).
SAP experiments using simulated draft variola
For the parameter values speciﬁed above, three SAP experi-
ments were simulated. In the ﬁrst, only the target sequences
were simulated into draft, and the NN sequences remained as
ﬁnished sequences. In the second, the NN sequences were
convertedtosimulateddraftandthetarget sequences remained
as ﬁnished. In the third, both target and NN sequences were
simulated into draft. In the second and third cases, all the NNs
were run through the draft simulator each time they were
chosen, so that the draft sequences (i.e. location and extent
of gaps and sequence errors) differ for the same genome
among samples. In the ﬁrst and third cases, the target
sequences must be aligned, and WGASA requires that one
of the sequences be a ﬁnished genome for reference. Thus,
for each random sample from the pool of target genomes, one
genome was randomly selected to be the ﬁnished genome, and
so was left as ﬁnished sequence, and the other genomes in the
sample were replaced with simulated draft sequence (by run-
ning through the draft simulator) before alignment. As with
NNs, target draft sequences differ for the same genome among
samples due to the randomness of the draft simulation each
time it is run. In addition, the target genome that is chosen to
be the ﬁnished, reference genome differs between samples,
and the other target genomes in the sample simulation are
replaced with simulated draft versions of the actual ﬁnished
sequences. Then these sequences were aligned using WGASA
and the SAP process was run as described above. A total of
1101 stochastic simulations per ‘experiment’ were performed,
requiring  18 min per simulation. Each simulation involved
randomlyselectingthesubsetoftargetandNNsequencestobe
included, simulating the draft data based on the ﬁnished gen-
omes, aligning the target sample, and ﬁnally running the DNA
Signature Pipeline. There were four combinations examined:
(i) ﬁnished variola and ﬁnished NN, (ii) draft variola and
ﬁnished NN, (iii) ﬁnished variola and draft NN and (iv)
draft variola and draft NN, with each of the draft runs repeated
for both low and high sequencing error rates. The combination
(iv) was also run with intermediate quality simulated draft
variola and low-quality simulated draft NNs. In total, there
were eight computational experiments for the ﬁnished and
simulated draft variola data.
Sequencing cost estimates
We have used the following function to estimate viral sequen-
cing costs, based on discussion with our laboratory colleagues
involved in sequencing and ﬁnishing.
Cost ¼ $1:2=bp · #bp in average Target strain · # finished Targets ½ 
þ $0:4=bp · #bp in average Target strain · #draft Targets ½ 
þ $1:2=bp · #bp in average NN strain · # finished NN ½ 
þ $0:4=bp · #bp in average NN strain · #draft NN ½ 
1
This is merely a rough estimate, and the actual costs of
sequencing any given organism may differ substantially
from this rule-of-thumb calculation. In Equation 1, it is
assumed that the cost of sequencing viruses does not decline
for sequencing second and subsequent isolates. While this may
be a false assumption in cases where isolates are similar to one
another, in other cases where the new sequences are divergent,
as isolates from different outbreaks or for viruses with rapid
mutation rates, the cost is especially unlikely to decline. In
addition, the $0.40/bp ﬁgure for draft of 6· to 8· coverage
could range from $0.30 to $0.50/bp using shotgun sequencing,
but may be as low as $0.10–$0.20/bp if primer walking works
well (i.e. known primer sites are found in new isolates).
Finishing could be 1–3 times more than the cost of draft,
so we used a factor of 2 times more (draft $0.4/bp, ﬁnished
$0.4 + 0.8/bp) in the equation above as a reasonable estimate.
With rapidly evolving sequencing technologies and costs,
theseareonlyroughguidesthatmay quickly become outdated.
RESULTS
Marburg virus
It may be substantially less expensive, on the order of 3-fold,
to generate draft compared with ﬁnished sequence data for an
organism like Marburg virus, according to estimates using
Equation 1. For example, for $45K, one could sequence either
twoﬁnishedgenomesoroneﬁnishedandthreedraft.However,
draft sequencing of this low quality (3· to 6·) for Marburg
causes a dramatic decline in the ability to computationally
eliminate regions of poor conservation, and thus to exclude
poor signature regions (Figure 2). This occurs because gaps
in the draft data of some of the sequences mask sequence
variation among strains. Using the best available data, all
six ﬁnished genomes, there is 75.2% sequence conservation.
The deﬁciencies of draft data give a false impression that there
is 92.6% sequence conservation (Table 1). Each additional
ﬁnished genome reduces the conserved fraction by 5%, com-
pared with a reduction of only 2% per genome for the draft
data.
The overestimation of conservation using draft Marburg
data also results in overestimation of the number of signature
candidates (Figure 3). Samples of four draft targets plus one
ﬁnished reference yield 43 signature candidates. A smaller
sample sizeofonlytwo draft targetsandone ﬁnished reference
generate upwards of 80 candidates. These results differ from
those using ﬁnished genomes, where the lack of sequence
conservation is more evident and there are zero TaqMan
signatures conserved among all strains. Most combinations
of four ﬁnished genomes are sufﬁcient to eliminate non-
conserved signatures (Figure 3A). Although predictions that
there are 0 signature candidates shared among all ﬁnished
strains may seem to argue against TaqMan methods, in fact
5846 Nucleic Acids Research, 2005, Vol. 33, No. 18this information provides important guidance for the develop-
ment of TaqMan signatures with degenerate bases or a set of
signatures that will, in combination, pick up all sequenced
strains. Other analyses indicate that there are TaqMan signa-
tures conserved among ﬁve of the six strains, so that two
signatures would form a minimal set that could detect both
the one divergent and the other ﬁve strains.
Variola virus simulated draft
Estimated sequencing costs of draft variola and draft NNs
indicate that draft may require only one-quarter to one-half
the costs of ﬁnished sequencing. Simulations of high-quality
draft data indicated that it is as good as ﬁnished data for
diagnostic signature prediction. The conservation range
plots (Figure 4A and B) are virtually identical for ﬁnished
and high-quality draft, and indicate that  98% of the genome
is conserved among sequenced isolates. For intermediate qual-
ity draft (Figure 4C) the conservation range plot is also similar
to that for ﬁnished sequence, showing that  97% of the gen-
ome appears to be conserved. The range plots for the number
of TaqMan signature candidates are very similar for ﬁnished
sequence data, high or intermediate quality draft target, and
high or low-quality draft NNs (Figure 5A–D).
In contrast to the results using high-quality simulated draft
or actual Marburg draft, simulations of low-quality variola
draft targetillustratethatsequence conservationmay beunder-
estimated compared with results with ﬁnished sequence data,
due to sequencing errors (Table 1 and Figure 4D). With low-
quality draft target, it appears that only 58% of the genome is
conserved among isolates.
Low-quality (high error rate) draft NN data, however, yield
results that are very similar to those with high-quality draft or
ﬁnished NN data, as long as the target sequence information is
of intermediate to high quality (Figure 5C–D andFigure 6): At
least four NN sequences are necessary to ensure that signature
regions are unique, whether the NN data are low- or high-
quality draft or ﬁnished. That is, our simulations indicate that
low-quality draft NN data are adequate for predicting DNA
signatures, as long as there is good quality target sequence
data. This results because errors in the NN sequences occur at
random locations that differ in each NN sequence. As long as
at least one of the NNs has enough correct sequence to elim-
inate each of the non-unique target regions, then the unique
regions of the target can be determined.
The results illustrated in the ﬁgures are emphasized by the
data in Table 1. This table shows the fraction of the target
genome that is conserved and conserved+unique, the number
of conserved+unique regions that are at least 18 contiguous
base pairs long and the number of base pairs in the largest of
these regions, since these are the sections that are of sufﬁcient
length for one or possibly more primers to be located. The
number of these regions is similar for ﬁnished data and for
draft with a low error rate. Low-quality draft (with a high
rate of sequencing errors) for the target data, however,
gives the false impression that there are fewer and shorter
regions that are conserved and suitable as signature regions
than is actually the case.
There is an artifact in some of our results that is a con-
sequence of the order in which we calculate conservation and
then uniqueness, although this does not affect the signatures
that are predicted. First, a conservation gestalt is generated
from the sequence alignment, in which non-conserved bases
are replaced by a dot (‘.’). Then uniqueness is calculated based
upon perfect matches of at least 18 bp long between the con-
servation gestalt and a large sequence database of non-target
Table 1. Summary of results using 28 variola genomes (finished or simulated draft as indicated) and 22 NN genomes from the Orthopox family, as well as the
finished and draft Marburg results
Species Simulated draft or
finished target
Draft or
finished NNs
Percent
conserved
sequence
(%)
Percent
conserved
and unique
sequence (%)
Number
TaqMan DNA
signature
candidates
Number
conserved
and unique
regions
Longest
conserved
and unique
region
Variola major virus Simulated draft,
high error rate
Finished 58.30 57.79 0 4 23
Variola major virus Simulated draft,
high error rate
Simulated draft,
high error rate
58.68 58.36 0 8 23
Variola major virus Finished Simulated draft,
high error rate
98.90 3.91 1 71 49
Variola major virus Simulated draft,
low error rate
Finished 98.61 4.60 1 89 49
Variola major virus Simulated draft,
low error rate
Simulated draft,
low error rate
98.65 4.43 0 86 49
Variola major virus Simulated draft,
low error rate
Simulated draft,
high error rate
98.76 4.42 0 88 49
Variola major virus Simulated draft,
intermediate error rate
Simulated draft,
high error rate
96.67 14.06 0 191 52
Variola major virus Finished Simulated draft,
low error rate
98.84 4.05 1 80 49
Variola major virus Finished Finished 98.90 3.99 1 76 49
Marburg virus Real draft, 3· to
6· coverage
Finished 92.60 83.31 43 250 198
Marburg virus Finished Finished 75.19 74.36 0 38 41
Thepercentofthetargetgenomethatisconservedvariesslightlyamongtherunsusingfinishedtargetsequencesbecausedifferentgenomeswererandomlyselectedto
be the reference strain in each multiple sequence alignment.
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may break up a region into conserved fragments of <18 bases
long, and as a result these short fragments are not tested for
uniqueness. Consequently, if there is a low level of conserva-
tion, then we may overestimate the fraction of the genome that
is unique. For example, in Table 1 the conserved+unique frac-
tion is 4% with ﬁnished variola target data, but is over-
estimated at 58% with low-quality draft. This artifact does
not, however, affect TaqMan signature prediction, since the
regions suitable for primers and probes must have at least 18
contiguous, conserved bases, and all of these are tested for
uniqueness, i.e. there is no underestimation of uniqueness in
conserved fragments that are at least 18 bp in length, and thus
no underestimate of uniqueness in the predicted signatures.
We are working to eliminate this issue in future versions of
the software.
Protein SAP results
Protein results show a large disparity between ﬁnished and
draft data. There are 113 protein signature candidates for ﬁn-
ished Marburg data compared with only two protein signature
candidates for Marburg draft (Figure 7). For variola, using all
available target data, 97, 14, 6 and 0 protein signatures are
predicted using ﬁnished, low error, intermediate error and high
error draft target data, respectively (Figure 8). Thus, sequen-
cing errors substantially reduce the detection of amino acid
sequence conservation, even if sequencing errors occur at the
low rate of 10
 4–10
 5 across most of the genome.
The pattern of how additional sequences reduce the number
of protein signature candidates also differs for draft compared
with ﬁnished sequence data. With ﬁnished data, there is a large
range in the number of peptide signature candidates predicted
with 17 or fewer variola genomes, and this range narrows
around the lower bound with >17 genomes. With 16 genomes,
the 75% quantile mark approaches the ﬁnal predicted number
of 97 signatures (Figure 8A). This pattern indicates that there
is a set of 97 peptides that are highly conserved among all
currently sequenced variolas, which are unlikely to be eroded
even as more sequence data are obtained. In other words,
additional sequence data are probably not needed at this
time in order to computationally predict good peptide signa-
ture targets, and as few as 16 ﬁnished target sequences would
most likely have been adequate to generate this same list of
 100 peptide signatures.
Draft data, in contrast, whether they are of low or high
quality, mask the above pattern (Figure 8B and C): the range
and 75th quantile of the number of peptide signatures gradu-
ally decline with each additional target sequence (rather than
a sudden, sharp drop as is seen with the ﬁnished data), sug-
gesting that additional target sequences would continue to
erode the number of peptide signatures. This occurs since
sequencing errors occur at random, in different locations
in each of the draft target genomes, and obscure the truly
conserved peptides. One might falsely infer from peptide
SAP results based on the draft data that additional sequencing
(beyond the 28 variola major genomes used here) would be
useful in generating peptide signature candidates. In actuality,
however, SAP analyses using the ﬁnished sequence data indic-
ate that there are already ample sequence data for peptide
signature prediction.
DISCUSSION AND CONCLUSIONS
The failure of draft sequencing for Marburg at 3· to 6·
coverage or of simulated variola draft with a high error rate
to facilitate the prediction of detection signatures highlights
a need for ﬁnished viral sequences, or at least for draft of high
quality such as 8·. Otherwise, a large number of signature
candidates either will fail in screening because they are incor-
rectly designated as conserved among strains (as observed
with the Marburg results), or too few regions will be classiﬁed
as conserved (as observed with variola), and thus not be
considered for signatures.
The variola simulations with intermediate to high-quality
draft (that is, a low error rate, approximating what one might
observe with 8· coverage) target and/or NN genomes deliver
virtually the same results as ﬁnished genomes. Considering
that it costs approximately three times as much to generate
ﬁnished sequence as it does draft, our analyses indicate that
investing in more high-quality draft target genomes is better
than investing in fewer ﬁnished genomes. For our analyses,
only one target strain must be ﬁnished, and the remaining
target sequences and all the NNs may be provided as draft.
Our results indicate that NN sequencing may be of low cov-
erage, and thus of low quality, without serious detriment to
signature prediction, as long as there are at least four NN draft
genome sequences.
If high-quality draft sequence is used, and it appears that
there is too little sequence conservation among target strains,
one might relax speciﬁcations for 100% conservation among
strains for diagnostic signature prediction. Calculations indic-
ate that it is often possible to generate signatures if one allows
a base to be considered ‘conserved’ if it is present in only a
fraction of the genomes (e.g. 75%) rather than the standard
requirement for 100% conservation when ﬁnished sequence
data are used. We have used this ‘ratio-to-win’ option to gen-
erate signature candidates for some highly divergent RNA
viruses (for which we have ﬁnished sequence), although usu-
ally our preference is to include degenerate bases, especially
when there are only a few bases with heterogeneity among
strains in a given signature candidate. Using a ratio-to-win
approach may be particularly important for the generation
of protein signature candidates, since draft target data severely
compromises the ability to detect conserved strings of amino
acids.
In summary, intermediate to high-quality draft sequencing
of target genomes, combined with low-quality draft sequen-
cing of close phylogenetic relatives, is sufﬁcient for the pre-
diction of DNA diagnostic signatures. Prediction of peptide/
protein signature candidates, in contrast, requires ﬁnished
sequencing to avoid substantial underestimation of conserved
peptide regions.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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APPENDIX
Marburg finished genomes used in these analyses
Fasta header Sequence
length
Sequence
description
gi|13489275|ref|NC_001608.2|
Marburg virus, complete
genome
19112 Marburg virus,
complete genome
Unpublished strain 1 19113 Unpublished sequence
of Marburg virus
PP3 19113 AY430365
PP4 19112 AY430366
Ozolin 19151 AY358025
Unpublished strain 2 19083 Unpublished sequence
of Marburg virus
Draft Marburg sequence data (intermediate versions of the same finished
sequences given above): unpublished strain 1, 17 contigs ranging from 859
bases to 29302 bases; PP3, 15 contigs ranging from 778 bases to 24884
bases; PP4, 15 contigs ranging from 779 bases to 19728 bases; unpublished
strain 2, 42 contigs ranging from 818 bases to 40767 bases.
Near neighbors for Marburg virus
Fasta header Sequence
length
gi|23630482|gb|AY142960.1| Zaire Ebola
virus strain Mayinga subtype Zaire,
complete genome
18959
gi|21702647|gb|AF499101.1| Zaire Ebola
virus strain Mayinga, complete genome
18960
gi|11761745|gb|AF272001.1| Zaire Ebola
virus strain Mayinga, complete genome
18959
gi|10313991|ref|NC_002549.1| Zaire Ebola
virus, complete genome
18959
gi|33860540|gb|AY354458.1| Zaire Ebola
virus strain Zaire 1995, complete genome
18961
Raw sequence of Ebola virus strain Zaire-95
from LLNL on Aug 292003 1:13PM
18961
gi|15823608|dbj|AB050936.1| Reston Ebola
virus genomic RNA, complete genome
18890
gi|22789222|ref|NC_004161.1| Reston Ebola
virus, complete genome
18891
Variola major sequence data
Fasta header Sequence
length
Sequence description
gi|9627521|ref|NC_001611.1|
Variola virus,
complete genome
185578 Variola virus,
complete genome
gi|623595|gb|L22579.1|VARCG
Variola major virus
(strain Bangladesh-1975)
complete genome
186103 Variola major
virus (strain
Bangladesh-1975)
complete genome
26 Unpublished
CDC sequences
Various Variola virus,
complete genome
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Fasta header Sequence
length
Sequence description
gi|20152989|gb|AF482758.1|
Cowpox virus strain Brighton
Red, complete genome
224501 Cowpox virus strain
Brighton Red,
complete genom
gi|30519405|emb|X94355.2|
CV41KBPL Cowpox virus strain
GRI-90, complete genome
223666 Cowpox virus strain
GRI-90, complete
genome
gi|30844336|ref|NC_003663.2|
Cowpox virus, complete genome
224499 Cowpox virus,
complete genome
1 cowpox genomes – Unpublished CDC
sequence
gi|17974913|ref|NC_003310.1|
Monkeypox virus,
complete genome
196858 Monkeypox virus,
complete genome
3 Monkeypox genomes Various Unpublished sequence
from the CDC
gi|29692106|gb|AY243312.1|
Vaccinia virus strain WR,
complete genome
194711 Vaccinia virus strain WR,
complete genome
gi|9790357|ref|NC_001559.1|
Vaccinia virus, complete genome
191737 Vaccinia virus,
complete genome
gi|47088326|gb|AY603355.1|
Vaccinia virus strain Acambis
3000 Modified Virus Ankara
(MVA), complete genome
166722 Vaccinia virus strain
Acambis 3000 Modified
Virus Ankara (MVA),
complete genome
3 Vaccinia genomes Various Unpublished CDC sequence
Fasta header Sequence
length
Sequence description
gi|22164589|ref|NC_004105.1|
Ectromelia virus,
complete genome
209771 Ectromelia virus,
complete genome
Ectromelia virus (Naval) 207620 http://athena.bioc.uvic.
ca/pbr/ncbi_gb/
pocsBrowser.php?
ECTV-Nav
1 Taterapox genome – Unpublished CDC
sequence
gi|18640237|ref|NC_003391.1|
Camelpox virus,
complete genome
205719 Camelpox virus,
complete genome
gi|19717929|gb|AY009089.1|
Camelpox virus CMS,
complete genome
202205 Camelpox virus CMS,
complete genome
1 Buffalopox genome – Unpublished CDC
sequence
gi|46401901|ref|NC_005858.1|
Rabbitpox virus,
complete genome
197731 Rabbitpox virus,
complete genome
RPXV-UTR_forward_1-197731 197731 Raw sequence of Rabbitpox
virus (strain Utrecht)
from poxvirus.org on
Aug 052003 1:59PM
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